The Role of GPR40 in Obesity and Type 2 Diabetes: A Study of Isolated Pancreatic Islets from Different Animal Models of Diabetes

被引：0
|
作者：
Balhuizen, Alexander
Kumar, Rajesh
Abaraviciene, Sandra Meidute
Amisten, Stefan
Olde, Bjorn
Lundquist, Ingmar
Salehi, Albert
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A457 / A457
页数：1
相关论文
共 50 条
  • [21] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    Kim, Jung Ho
    Lee, Seolhee
    Shin, Chorong
    Jun, Yearin
    Hong, Dahae
    Lee, Don-Gil
    Jang, Eunhye
    Kim, Jisu
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [22] CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes
    Bazydlo-Guzenda, Katarzyna
    Buda, Pawel
    Kozlowska, Izabela
    Mach, Mateusz
    Teska-Kaminska, Malgorzata
    Stelmach, Filip
    Wasinska-Kalwa, Malgorzata
    Galazka, Kinga
    Dubiel, Krzysztof K.
    Pieczykolan, Jerzy S.
    Wieczorek, Maciej
    DIABETES, 2019, 68
  • [23] Discovery of ZYDG2: a potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes
    Jain, Mukul R.
    Giri, Suresh R.
    Trivedi, Chitrang J.
    Bhoi, Bibhuti B.
    Rath, Akshyaya Chandan
    Rathod, Rohan M.
    Sundar, Rajesh
    Bandyopadhyay, Debdutta
    Ramdhave, Rashmi
    Patel, Gautam D.
    Srivastava, Brijesh Kumar
    Desai, Ranjit C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (04):
  • [24] SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity
    Ueno, Hikaru
    Ito, Ryo
    Abe, Shin-ichi
    Ookawara, Mitsugi
    Miyashita, Hirohisa
    Ogino, Hitomi
    Miyamoto, Yasufumi
    Yoshihara, Tomoki
    Kobayashi, Akihiro
    Tsujihata, Yoshiyuki
    Takeuchi, Koji
    Watanabe, Masanori
    Yamada, Yukio
    Maekawa, Tsuyoshi
    Nishigaki, Nobuhiro
    Moritoh, Yusuke
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (02): : 172 - 181
  • [25] A selective GPR40 (FFAR1) agonist provides immediate and durable glucose control in rodent models of type 2 diabetes
    Chen, Y.
    DIABETOLOGIA, 2014, 57 : S56 - S56
  • [26] Epigenetic modifications in pancreatic islets from patients with type 2 diabetes
    Ling, C. A.
    Dayeh, T.
    Volkov, P.
    Yang, B.
    Olsson, A.
    Hall, E.
    Ronn, T.
    Wollheim, C.
    Nitert, M. D.
    DIABETOLOGIA, 2012, 55 : S48 - S49
  • [27] Evidence for a Role of Frataxin in Pancreatic Islets Isolated from Multi-Organ Donors with and Without Type 2 Diabetes Mellitus
    Del Guerra, S.
    D'Aleo, V.
    Gualtierotti, G.
    Pandolfi, R.
    Boggi, U.
    Vistoli, F.
    Barnini, S.
    Filipponi, F.
    Del Prato, S.
    Lupi, R.
    HORMONE AND METABOLIC RESEARCH, 2012, 44 (06) : 471 - 475
  • [28] In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    Lee, Don-Gil
    Kim, Jung Ho
    Hong, Dahae
    Shin, Chorong
    Jang, Eunhye
    Kim, Jisu
    Lee, Seolhee
    Jun, Yearin
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [29] Animal models of type 2 diabetes with reduced pancreatic β-cell mass
    Masiello, P
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (5-6): : 873 - 893
  • [30] Type 2 diabetes: Microvascular ischemia of pancreatic islets?
    Tal, Michael G.
    MEDICAL HYPOTHESES, 2009, 73 (03) : 357 - 358
12345